

Ranjana H Advani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3936977/publications.pdf>

Version: 2024-02-01

221
papers

23,712
citations

18482

62
h-index

7950

149
g-index

224
all docs

224
docs citations

224
times ranked

20146
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	1.4	5,965
2	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
3	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2013, 31, 88-94.	1.6	991
4	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	30.7	927
5	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.	1.6	890
6	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 372, 1430-1440.	27.0	810
7	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 1711-1721.	27.0	796
8	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	1.6	634
9	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	13.7	517
10	Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 368, 1408-1416.	27.0	485
11	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	1.4	370
12	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	1.4	349
13	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016, 8, 364ra155.	12.4	348
14	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	1.6	313
15	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	1.4	280
16	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1183-1194.	1.4	276
17	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	1.6	256
18	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015, 125, 1394-1402.	1.4	242

#	ARTICLE	IF	CITATIONS
19	Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and SÅ©zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology, 2015, 33, 3750-3758.	1.6	235
20	Stage I and II Follicular Non-Hodgkinâ€™s Lymphoma: Long-Term Follow-Up of No Initial Therapy. Journal of Clinical Oncology, 2004, 22, 1454-1459.	1.6	211
21	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clinical Cancer Research, 2012, 18, 248-255.	7.0	204
22	Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood, 2018, 132, 40-48.	1.4	199
23	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 2012, 120, 3280-3287.	1.4	188
24	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematology, the, 2019, 6, e254-e265.	4.6	184
25	Gene Expressionâ€‘Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 692-700.	1.6	176
26	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 2017, 130, 2709-2717.	1.4	176
27	Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2009, 27, 4371-4377.	1.6	175
28	A Phase <sc>II</sc> trial of Belinostat (<sc>PXD</sc>101) in patients with relapsed or refractory peripheral or cutaneous Tâ€™cell lymphoma. British Journal of Haematology, 2015, 168, 811-819.	2.5	172
29	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. Blood, 2016, 128, 1321-1328.	1.4	161
30	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology, 2019, 37, 3359-3368.	1.6	161
31	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood, 2012, 120, 560-568.	1.4	157
32	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. Journal of Clinical Oncology, 2014, 32, 3137-3143.	1.6	153
33	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 2016, 4, 910-916.	3.4	146
34	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology and Oncology, 2014, 7, 24.	17.0	144
35	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. Clinical Cancer Research, 2011, 17, 4125-4135.	7.0	126
36	Clonal architecture of <i><sc>CXCR</sc>4</i> <sc>WHIM</sc>-like mutations in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744.	2.5	122

#	ARTICLE	IF	CITATIONS
37	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	1.4	117
38	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. <i>Blood</i> , 2017, 129, 2519-2525.	1.4	115
39	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and ^Stanford ^V in older ^Hodgkin lymphoma patients: a comprehensive analysis from the ^North ^American intergroup trial ^E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	2.5	111
40	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.	1.4	109
41	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	4.9	107
42	The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	4.1	106
43	Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. <i>Blood</i> , 2013, 121, 745-751.	1.4	105
44	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	1.6	102
45	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	16.8	102
46	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	1.6	98
47	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 912-918.	1.6	96
48	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , the, 2020, 7, e827-e837.	4.6	96
49	A multicentre study of primary breast diffuse large ^B-cell lymphoma in the rituximab era. <i>British Journal of Haematology</i> , 2014, 165, 358-363.	2.5	91
50	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	1.6	86
51	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	1.4	86
52	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2021, 8, e410-e421.	4.6	83
53	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the ^{BCL}2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory ^{CD}20⁺ lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	2.5	80
54	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1167-1176.	7.0	77

#	ARTICLE	IF	CITATIONS
55	Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. <i>Clinical Cancer Research</i> , 2018, 24, 4110-4118.	7.0	77
56	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.	17.0	76
57	Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. <i>Leukemia and Lymphoma</i> , 2007, 48, 521-525.	1.3	73
58	Gray zone lymphoma with features intermediate between classical <sc>H</sc>odgkin lymphoma and diffuse large <sc>B</sc>-cell lymphoma: <sc>C</sc>haracteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	4.1	71
59	A phase <sc>II</sc> study of cyclophosphamide, etoposide, vincristine and prednisone (<sc>CEOP</sc>) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral Tâ€cell lymphoma (<sc>PTCL</sc>): final results from the Tâ€cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	2.5	71
60	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. <i>Oncotarget</i> , 2018, 9, 13023-13035.	1.8	70
61	A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C ?, administered as a 21-day infusion to patients with advanced ovarian carcinoma. <i>Cancer</i> , 2004, 100, 321-326.	4.1	65
62	A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1373-1379.	1.3	65
63	Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 111-121.	2.3	58
64	Brutonâ€™s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 121-133.	2.5	57
65	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018, 131, 2120-2124.	1.4	56
66	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	1.4	53
67	Venetoclax in Previously Treated Waldenstrâ€™m Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	1.6	53
68	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	4.1	51
69	Responseâ€adapted therapy for aggressive nonâ€Hodgkin's lymphomas based on early [18F] FDGâ€PET scanning: ECOGâ€ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65.	2.5	50
70	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
71	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	2.5	49
72	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	4.1	47

#	ARTICLE	IF	CITATIONS
73	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	1.3	46
74	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1100-1118.	0.8	46
75	How I treat nodular lymphocyte predominant Hodgkin lymphoma. <i>Blood</i> , 2013, 122, 4182-4188.	1.4	45
76	Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. <i>British Journal of Haematology</i> , 2018, 180, 164-166.	2.5	45
77	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	4.1	43
78	Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2010, 16, 2167-2175.	7.0	42
79	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.	3.7	42
80	Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. <i>Radiology</i> , 2016, 280, 220-229.	7.3	39
81	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578.	1.3	36
82	Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	1.6	36
83	CD20-Targeted Therapy Ablates <i>De Novo</i> Antibody Response to Vaccination but Spares Preestablished Immunity. <i>Blood Cancer Discovery</i> , 2022, 3, 95-102.	5.0	36
84	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refractory B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 182-182.	1.4	35
85	A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013, 122, 251-251.	1.4	34
86	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	1.6	33
87	A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 848-848.	1.4	33
88	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
89	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012, 120, 60-60.	1.4	32
90	Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. <i>Blood</i> , 2015, 126, 470-470.	1.4	31

#	ARTICLE	IF	CITATIONS
91	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 703-710.	1.3	29
92	How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1Âh: the Stanford Approach. <i>Molecular Imaging and Biology</i> , 2018, 20, 324-335.	2.6	29
93	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.2	29
94	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 179-186.	2.5	28
95	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	3.7	28
96	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	5.2	28
97	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 193-200.	0.4	27
98	Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. <i>Acta Haematologica</i> , 2020, 143, 40-50.	1.4	27
99	Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 718-720.	1.3	26
100	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	7.0	26
101	Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, e86-e90.	2.5	25
102	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585.	1.4	25
103	Efficacy and Late Effects of Stanford V Chemotherapy and Radiotherapy in Untreated Hodgkin's Disease: Mature Data in Early and Advanced Stage Patients.. <i>Blood</i> , 2004, 104, 308-308.	1.4	22
104	Optimal Therapy of Advanced Hodgkin Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 310-316.	2.5	21
105	Speeding up PET/MR for cancer staging of children and young adults. <i>European Radiology</i> , 2016, 26, 4239-4248.	4.5	20
106	Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 17-29.	2.5	19
107	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	2.5	19
108	SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin's Lymphoma: Evidence of Antitumor Activity from a Phase I Study.. <i>Blood</i> , 2006, 108, 695-695.	1.4	19

#	ARTICLE	IF	CITATIONS
109	Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e466-e468.	3.5	18
110	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019, 134, 238-238.	1.4	18
111	Assessment of Favorable (F) Versus Unfavorable (U) Early Stage Hodgkin's Disease (HD); the Stanford V + Radiotherapy (RT) Experience.. <i>Blood</i> , 2005, 106, 1932-1932.	1.4	17
112	Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin's Disease (NLPHD).. <i>Blood</i> , 2007, 110, 644-644.	1.4	17
113	Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1105-1105.	1.4	17
114	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	1.8	16
115	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016, 128, 621-621.	1.4	16
116	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8519-8519.	1.6	16
117	Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. <i>Blood</i> , 2012, 120, 797-797.	1.4	15
118	Risk-adapted therapy for advanced-stage Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 200-206.	2.5	14
119	The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. <i>Blood</i> , 2011, 118, 442-442.	1.4	14
120	Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1741-1741.	1.4	14
121	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014, 124, 3095-3095.	1.4	14
122	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 104-104.	1.4	14
123	Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 99-106.	0.8	13
124	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). <i>Blood</i> , 2018, 132, 679-679.	1.4	13
125	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010, 116, 961-961.	1.4	13
126	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. <i>Blood</i> , 2011, 118, 3701-3701.	1.4	13

#	ARTICLE	IF	CITATIONS
127	Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. <i>Blood</i> , 2014, 124, 3092-3092.	1.4	13
128	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014, 124, 4453-4453.	1.4	13
129	A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 604-608.	1.3	12
130	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- γ , δ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , 2016, 128, 2979-2979.	1.4	12
131	Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. <i>Clinical Cancer Research</i> , 2022, 28, 1294-1301.	7.0	12
132	Management of Advanced Stage Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 241-247.	4.9	11
133	Stage I-IIA Non-Bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1374-1379.	0.8	11
134	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	2.7	11
135	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.	5.2	11
136	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011, 118, 443-443.	1.4	11
137	Phase I/II Study of CHOEP Plus Lenalidomide As Initial Therapy for Patients with Stage II-IV Peripheral T-Cell Lymphoma: Phase II Results. <i>Blood</i> , 2018, 132, 2899-2899.	1.4	10
138	Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 543-54.	0.3	10
139	Cancer Vaccines and T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S97-S101.	2.0	9
140	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 67-75.	0.8	9
141	Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). <i>Blood</i> , 2018, 132, 1635-1635.	1.4	9
142	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. <i>Blood</i> , 2012, 120, 2746-2746.	1.4	9
143	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 4144-4144.	1.4	9
144	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	1.6	9

#	ARTICLE	IF	CITATIONS
145	Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). <i>Oncotarget</i> , 2018, 9, 766-773.	1.8	8
146	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	2.5	8
147	18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2883-2893.	6.4	8
148	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2019, 134, 468-468.	1.4	8
149	Phase II Study of Bortezomib in Waldenström's Macroglobulinemia: Results of WMCTG Trial 03-248.. <i>Blood</i> , 2005, 106, 490-490.	1.4	8
150	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)., <i>Blood</i> , 2011, 118, 3711-3711.	1.4	8
151	Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1540-1540.	1.4	8
152	Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. <i>Blood</i> , 2015, 126, 2706-2706.	1.4	8
153	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 2984-2984.	1.4	8
154	Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8505-8505.	1.6	8
155	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2930-2930.	1.4	8
156	Risk stratification in extranodal natural killer/T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1395-1405.	2.4	7
157	XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma. <i>Hematological Oncology</i> , 2015, 33, 90-95.	1.7	7
158	New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 626-636.	3.8	7
159	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	3.7	7
160	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 1626-1626.	1.4	7
161	Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 649-649.	1.4	7
162	Customized Targeted Therapy in Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 105-122.	2.2	6

#	ARTICLE	IF	CITATIONS
163	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Archives of Pathology and Laboratory Medicine, 2016, 140, 1225-1227.	2.5	6
164	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. Blood, 2011, 118, 3091-3091.	1.4	6
165	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. Blood, 2012, 120, 2745-2745.	1.4	6
166	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood, 2013, 122, 4386-4386.	1.4	6
167	First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology, 2021, 39, 3006-3006.	1.6	5
168	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. Blood, 2014, 124, 629-629.	1.4	5
169	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. Blood, 2016, 128, 2992-2992.	1.4	5
170	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2993-2993.	1.4	5
171	Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8506-8506.	1.6	5
172	Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. Oncology, 2022, 36, 51-58.	0.5	5
173	Novel Approaches in Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 875-890.	2.2	4
174	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 655-655.	1.4	4
175	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood, 2011, 118, 94-94.	1.4	4
176	Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. Blood, 2014, 124, 1745-1745.	1.4	4
177	Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. Blood, 2015, 126, 4860-4860.	1.4	4
178	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood, 2015, 126, 176-176.	1.4	4
179	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. Blood, 2017, 130, 826-826.	1.4	4
180	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2019, 134, 2022-2022.	1.4	4

#	ARTICLE	IF	CITATIONS
181	Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e376-e385.	3.8	3
182	Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Journal of Oncology Practice, 2017, 13, e673-e682.	2.5	3
183	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. Blood, 2011, 118, 1603-1603.	1.4	3
184	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	1.4	3
185	Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. Blood, 2015, 126, 1536-1536.	1.4	3
186	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. Blood, 2021, 138, 878-878.	1.4	3
187	Reply to J. Wang et al. Journal of Clinical Oncology, 2019, 37, 755-757.	1.6	2
188	Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. Nuclear Medicine Communications, 2021, 42, 792-799.	1.1	2
189	Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. Blood, 2018, 132, 2937-2937.	1.4	2
190	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. Blood, 2012, 120, 1618-1618.	1.4	2
191	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. Blood, 2013, 122, 3044-3044.	1.4	2
192	Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.. Journal of Clinical Oncology, 2012, 30, 8070-8070.	1.6	2
193	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome d'Adultes. Blood, 2013, 122, 3045-3045.	1.4	2
194	Bulky mediastinal classical Hodgkin lymphoma in young women. Oncology, 2014, 28, 253-6, 258-60, C3.	0.5	2
195	Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Radiotherapy and Oncology, 2018, 129, 507-512.	0.6	1
196	Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. JCO Oncology Practice, 2020, 16, e902-e911.	2.9	1
197	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	1.4	1
198	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood, 2019, 134, 2834-2834.	1.4	1

#	ARTICLE	IF	CITATIONS
199	The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. Blood, 2015, 126, 1486-1486.	1.4	1
200	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	1.4	1
201	Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 756-756.	1.4	1
202	The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project. Blood, 2016, 128, 921-921.	1.4	1
203	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. Blood, 2018, 132, 2838-2838.	1.4	1
204	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. Blood, 2019, 134, 4571-4571.	1.4	1
205	Outcome of Patients with Advanced Hodgkin Lymphoma Who Are Either Refractory to or Relapsed After Primary Therapy with the Stanford V Regimen. Blood, 2010, 116, 4828-4828.	1.4	0
206	Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. Blood, 2011, 118, 3068-3068.	1.4	0
207	Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience.. Journal of Clinical Oncology, 2012, 30, 8060-8060.	1.6	0
208	Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. Blood, 2012, 120, 4779-4779.	1.4	0
209	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	1.4	0
210	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. Journal of Clinical Oncology, 2014, 32, 8504-8504.	1.6	0
211	Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.. Journal of Clinical Oncology, 2014, 32, 8544-8544.	1.6	0
212	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. Blood, 2014, 124, 1703-1703.	1.4	0
213	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. Blood, 2015, 126, 2702-2702.	1.4	0
214	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 93-93.	1.4	0
215	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. Blood, 2018, 132, 2861-2861.	1.4	0
216	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood, 2019, 134, 4027-4027.	1.4	0
218	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. Blood, 2019, 134, 1553-1553.	1.4	0
219	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	1.4	0
220	PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy. Blood, 2020, 136, 17-18.	1.4	0
221	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. Blood, 2020, 136, 45-46.	1.4	0